DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "US Biosimilars Market Opportunity & Clinical Pipeline Analysis" report to their offering.
Biologics have dominated the US market for several decades due to absence of worthy competitor in different disease segment. In coming years, this situation is expected to change as biosimilars are expected to be commercialized. Zarxio, first US biosimilar, has created lot of enthusiasm among masses but some physicians, investigators and payers have reservation against biosimilars.
This scenario may cause hindrance in uptake of biosimilars in coming years. To increase acceptance rates, biosimilar developers have to produce head-to-data confirming pharmacological efficacy. Biosimilars are also expected to have higher cost-effectiveness promoting patients to switch from biologics.
Key Topics Covered:
- US Biosimilars Market Introduction
- US Biosimilars Regulatory Scenario
- Unique Features of US Biosimilars Market
- Impact of Biosimilars in US Market
- Impact of Reimbursement Policies on US Biosimilars Market
- Zarxio: First Approved Biosimilar in US
- US Biosimilar Clinical Pipeline By Company, Indication & Phase
- US Biosimilar Clinical Pipeline: 104 Biosimilars
- Marketed Biosimilars: 1 Biosimilar
Companies Mentioned:
- Amgen
- Apotex
- Boehringer Ingelheim
- Celltrion
- Coherus BioSciences
- Eli Lilly
- EPIRUS Biopharmaceuticals
- Finox Biotech
- Harvest Moon Pharmaceuticals
- Hospira
- Intas Biopharmaceuticals
- Juno Therepeutics (Opus Bio)
- Merck
- Momenta Pharmaceuticals
- Mylan
- Nora Therapeutics
- Novartis
- Oncobiologics
- Pfenex
- Pfizer
- Sandoz
- Wockhardt
Report Structure:
1. US Biosimilars Market Introduction
2. US Biosimilars Regulatory Scenario
3. Unique Features of US Biosimilars Market
4. Impact of Biosimilars in US Market
5. New Biosimilar Categories with High Commercialization Potential
6. Impact of Reimbursement Policies on US Biosimilars Market
7. Biobetters: Middle Ground between Biosimilars & Biologics
8. US Biosimilars Market Overview
9. Zarxio: First Approved Biosimilar in US
10. US Biosimilars Market Dynamics
11. US Biosimilars Commercialization Challenges
12. US Biosimilars Future Prospects
13. US Biosimilars Market Guidelines
14. US Biosimilar Clinical Pipeline By Company, Indication & Phase
15. Suspended & Discontued Biosimialrs in Clinical Pipeline
16. Competitive Landscape
For more information visit http://www.researchandmarkets.com/research/3bpvbf/us_biosimilars
